Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Fiche publication
Date publication
juin 2019
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Dr BOIDOT Romain, Pr GHIRINGHELLI François, Dr MIRJOLET Céline, Dr LIMAGNE Emeric, Dr DERANGERE Valentin, Dr FUMET Jean-David, Dr THIBAUDIN Marion
Tous les auteurs :
Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C
Lien Pubmed
Résumé
Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors (ICI) in association with RT. However, only few trials aim to optimize the RT fractionation to improve efficacy of these associations. Here we sought to characterize the effect of different fractionation protocols on immune response with a view to associating them with ICI.
Mots clés
Colorectal cancer, Immune response, Immunotherapy, Radiotherapy fractionation
Référence
J Immunother Cancer. 2019 Jun 25;7(1):160